Physician profile
Nermin Aly
NPI 1184486193
$527.04
in general payments reported to CMS, 2019-2025
13 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $301 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Shionogi INC | $109.65 | 2024 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $85.87 | 2024-2025 | Andexxa |
| Vanda Pharmaceuticals INC. | $36.40 | 2025 | Ponvory |
| Lilly USA, LLC | $21.82 | 2025 | Kisunla |
| Pfizer INC. | $21.77 | 2025 | |
| Springworks Therapeutics, INC. | $20.41 | 2025 | Gomekli |
| Neurocrine Biosciences, INC. | $20.08 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.61 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2025 | |
| Acadia Pharmaceuticals INC | $16.65 | 2025 | Nuplazid |
| Ucb, INC. | $15.93 | 2025 | Nayzilam |
| Eisai INC. | $15.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nermin Aly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.